Relapse of P. vivax infection is more likely in patients who received low dose primaquine therapy.
HELP TO MAKE OPEN ACCESS A WORLDWIDE STANDARD FOR PUBLISHING SCIENCE
A very important point to make about this campaign is that THE PETITION CAN BE SIGNED BY ANYONE over 13 years in age with an email address, and from all parts of the world. So by signing this petition YOU CAN MAKE A DIFFERENCE. The more signatures there are , the louder the message will be and the more chance there will be for rapid change.
Please sign and tell your colleagues, family, friends that they can sign too.
Quick question: For those of you who work in a recombinant DNA lab, what is the most hazardous chemical that you use on a daily basis? To put it another way, what chemical do you ALWAYS wear gloves to handle? Probably the same one that I do, but risk perception and reality aren’t always the same thing.
When it comes to genetic control of mosquitoes, risks are a hot topic, so it’s useful to consider the answer to this question.
This is the last of a string articles from a project on use of larviciding, using b.sphaericus granules of a "kitchen counter" formulation, and bit of environmental engineering for mosquito control. The method provided better than 90% mosquito reduction in the intervention zone. The results were detailed in previous reports from the study in two urban areas in Burkina Faso.
This system offers a flexible and safe approach to testing the in vivo activity of novel antimalarials.
IVCC and Syngenta reach key milestone in development of new insecticide for malaria mosquito control.
• Field trials show Actellic® 300CS can provide at least 8 months control of pyrethroid resistant mosquitoes
• Actellic® 300CS micro-encapsulated formulation submitted to WHOPES
• Major step forward in development of new products for malaria control
By accessing, viewing, downloading or otherwise using MalariaWorld or any webpage or feature available through MalariaWorld, any information provided as part of the MalariaWorld services, or any related emails, blogs, forum, poll, newsletters or services (hereinafter collectively “MalariaWorld” or the “Services”), or by registering you become a MalariaWorld user (“User”).